Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Primary cutaneous follicle centre lymphoma medical therapy

Introduction

Overvew

Overvew

The predominant therapy for primary cutaneous follicle centre lymphoma is radiotherapy. Adjunctive chemotherapy may be required.

Medical Therapy

Medical Therapy

  • Surgical removal and/or radiotherapy is given for localized disease.[1][2]
  • Radiation using multiple radiation fields is given if the disease has wider extent with grouped lesions.[1]:314[3][4][2]
  • For the less common situation of more extensive disease (still confined to skin), rituximab without chemotherapy is used.[1][3][4][2]Intralesional interferon alpha (IFN-α)[5]and intralesional rituximab have been used.[1][5]
  • There are mixed results of CHOP and R-CHOP. In one study on 104 patients CHOP chemotherapy demonstrated complete responses in 85 percent of the patients.[6]
  • There are also published case reports presented clinical responses to topical class 1 corticosteroids.[7]
  • Approximately one-third of primary cutaneous follicle centre lymphoma relapse, usually in the skin; treatment is similar to initial management[2] and overall survival remains excellent.[8]
References

References

  1. ↑ 1.0 1.1 1.2 1.3 Jaffe, ES (2011). Hematopathology (1st ed.). Elsevier Saunders. ISBN 9780721600406. Unknown parameter |coauthors= ignored (help)
  2. ↑ 2.0 2.1 2.2 2.3 Wilcox RA (2015). “Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management”. Am. J. Hematol. 90 (1): 73–6. doi:10.1002/ajh.23863. PMID 25535037.
  3. ↑ 3.0 3.1 Armitage, JO; Mauch PM; Harris NL; et al. (2010). “Chapter 24”. Non-Hodgkin Lymphomas (2nd ed.). Lippincott Williams & Wilkins. ISBN 9780781791168.
  4. ↑ 4.0 4.1 Sokol L, Naghashpour M, Glass LF (2012). “Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management”. Cancer Control. 19 (3): 236–44. PMID 22710899.
  5. ↑ 5.0 5.1 Senff NJ, Noordijk EM, Kim YH, et al. (2008). “European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas”. Blood. 112 (5): 1600–9. doi:10.1182/blood-2008-04-152850. PMID 18567836.
  6. ↑ Senff NJ, Noordijk EM, Kim YH, Bagot M, Berti E, Cerroni L; et al. (2008). “European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas”. Blood. 112 (5): 1600–9. doi:10.1182/blood-2008-04-152850. PMID 18567836.
  7. ↑ Suárez AL, Querfeld C, Horwitz S, Pulitzer M, Moskowitz A, Myskowski PL (2013). “Primary cutaneous B-cell lymphomas: part II. Therapy and future directions”. J Am Acad Dermatol. 69 (3): 343.e1–11, quiz 355-6. doi:10.1016/j.jaad.2013.06.011. PMID 23957985.
  8. ↑ Suárez AL, Querfeld C, Horwitz S, et al. (2013). “Primary cutaneous B-cell lymphomas: part II. Therapy and future directions”. J. Am. Acad. Dermatol. 69 (3): 343.e1–11, quiz 355–6. doi:10.1016/j.jaad.2013.06.011. PMID 23957985.


Template:WikiDoc Sources

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]